Bristol-Myers +3% premarket on Q4 beat

Bristol-Myers Squibb (BMY) Q4 results: Revenues: $7,945M (+33.0%); R&D Expense: $7,662M (+34.1%).

Net loss: ($1,056M); loss/share: ($0.55); non-GAAP Net Income: $2,374M (+45.0%); non-GAAP EPS: $1.22 (+29.8%).

Key product sales: Eliquis: $2,034M (+19%); Opdivo: $1,763M (-2%); Revlimid: $1,299M; Orencia: $792M (+8%); Sprycel: $549M (+2%); Yervoy: $385M (unch); Pomalyst/Imnovid: $322M.

2020 guidance: Revenue: $40.5B – 42.5B vs. $42.21B S&P Capital IQ Consensus; EPS: $0.75 – 0.95; non-GAAP EPS: $6.00 – 6.20 vs. $6.20 S&P Capital IQ Consensus.

2021 guidance: Non-GAAP EPS: $7.15 – 7.45.

Shares are up 3% premarket.

Previously: Bristol-Myers Squibb EPS beats by $0.28, beats on revenue (Feb. 6)

https://seekingalpha.com/news/3539183-bristol-myersplus-3-premarket-on-q4-beat